Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 2261-2270 of 10941

Edit search filters
  1. A Trial to Investigate Long Term Effectiveness and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

    Rochester, MN

  2. Renal Function Using Quantitative MRI, Histopathology, and Liquid Biomarkers

    Rochester, MN

  3. HEAL-LAA Clinical Trial (HEAL-LAA)

    Rochester, MN

  4. A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with CAA

    Jacksonville, FL

  5. A Study to Assess the Effectiveness and Safety of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

    Jacksonville, FL

  6. Study of LNP023 (iptacopan) in patients with ANCA-associated vasculitis

    Rochester, MN

  7. Use of New Generation Fetoscopes in Pregnancies Affected by Fetal Diseases Amenable to Fetoscopy Therapy

    Rochester, MN

  8. A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of NIO752 in Participants with Progressive Supranuclear Palsy

    Rochester, MN

  9. Cerebrospinal Fluid Biomarkers for Brain Tumors

    Rochester, MN

  10. Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Systemic Sclerosis

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer